8-KOther Events

QUEST DIAGNOSTICS INC 8-K Report (Jul 25, 2002)

Filed July 25, 2002For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) filed an 8-K on July 25, 2002, to correct a previously reported figure related to its second quarter 2002 financial performance. The primary purpose of this filing is to provide an updated cash flow from operations for the quarter ended June 30, 2002. This correction is important for investors seeking accurate financial data to assess the company's operational performance and financial health. The company reported that the correct cash flow from operations for the second quarter of 2002 was $165 million, an upward revision from the initially communicated $156 million. Quest Diagnostics explicitly states that no other information provided in their July 22, 2002 press release or their subsequent investor conference call on July 23, 2002, has changed. This implies that other key financial metrics and operational updates remain as previously disclosed.

Key Highlights

  • 1Correction of Cash Flow from Operations: The reported cash flow from operations for Q2 2002 has been revised upwards to $165 million from $156 million.
  • 2Date of Report: July 23, 2002 (earliest event reported).
  • 3Filing Date: July 25, 2002.
  • 4Purpose: Regulation FD Disclosure to correct a financial figure.
  • 5No Other Changes: All other information previously communicated in the July 22, 2002 press release and July 23, 2002 conference call remains accurate.
  • 6Authorized Signatory: Thomas F. Bongiorno, Vice President, Controller and Chief Accounting Officer.

Frequently Asked Questions

The main purpose of this 8-K filing is to correct a previously disclosed financial figure. Specifically, Quest Diagnostics is revising its reported cash flow from operations for the second quarter of 2002.

The cash flow from operations for the quarter ended June 30, 2002, was corrected. The revised amount is $165 million, up from the initially reported $156 million.

No, Quest Diagnostics explicitly states that there are no other changes to the information communicated in their press release dated July 22, 2002, or in their investor conference call on July 23, 2002.

The filing was signed by Thomas F. Bongiorno, who holds the positions of Vice President, Controller, and Chief Accounting Officer at Quest Diagnostics Incorporated.